Insights Center

Thought leadership, news, events — you will find them all here, right at your fingertips. We’ve consolidated the firm’s most popular content in one, easy to search location. Enter a key word or phrase to find pertinent blog posts, articles, press releases, and upcoming events.

Featured

Mintz Direct

On our new Mintz Direct page, Mintz thought leaders across industries and practice areas offer timely insights on developments that impact our clients and communities. Visit the Mintz Direct page to hear what our experienced attorneys and professionals are saying about what’s happening now.

Mintz Viewpoints

Use quotation marks to search for an exact phrase (e.g. “class action”)

Published

Showing 10609 - 10616 of 12140 results

It’s The End of the World as We Know It: Life after Non-Competes in Massachusetts (Why You Should Feel Fine)

April 17, 2014| Blog| Viewpoint

Is 4-3 the New 3-2? FTC Continues to Target Pharmaceutical Mergers

April 16, 2014| Alert| Viewpoint

ML Strategies Posts Weekly Health Care Update on April 14, 2014

April 15, 2014| Blog| Viewpoint

Unified Residency Accreditation System To Be Launched

April 14, 2014| Blog| Viewpoint

FTC Data Security Authority Confirmed, For Now: Wyndham’s Motion to Dismiss Denied

April 14, 2014| Alert| Viewpoint

Privacy Monday - April 14, 2014: Heartbleed Headaches

April 14, 2014| Blog| Viewpoint

The Affordable Care Act—Countdown to Compliance for Employers, Week 37: Stalking the Elusive “Variable Hour Employee”

April 14, 2014| Blog| Viewpoint

A Check on the EEOC Attack on the Credit Check

April 14, 2014| Blog| Viewpoint

News & Press Releases

Mintz Advises Charlesbank Capital Partners on Acquisition of Q6 Cyber

September 15, 2025

Mintz Advises on LB Pharmaceuticals’ $285 Million Initial Public Offering

September 12, 2025

Mintz advised the underwriters in connection with a $285 million initial public offering by LB Pharmaceuticals Inc of 19,000,000 shares of common stock at an initial public offering price of $15.00 per share. The aggregate gross proceeds to LB Pharmaceuticals from this offering were approximately $285 million before deducting underwriting discounts and commissions and other offering expenses. In addition, LB Pharmaceuticals granted the underwriters a 30-day option to purchase up to an additional 2,850,000 shares of common stock at the initial public offering price, less underwriting discounts and commissions. The shares began trading on the Nasdaq Global Market on September 11, 2025 under the ticker symbol “LBRX.”

Mintz Advises the Placement Agents in CAMP4’s up to $100 Million Private Placement

September 12, 2025

Mintz advised the placement agents in connection with CAMP4's up to $100 million private placement. The private placement included upfront gross proceeds of $50 million in exchange for common stock (and pre-funded warrants in lieu of common stock for certain investors). In addition, CAMP4 will be eligible to receive up to an additional $50 million in gross proceeds in exchange for common stock (and pre-funded warrants for certain investors), subject to achieving pre-specified milestones, including receipt of regulatory clearance to initiate a Phase 1/2 clinical trial in SYNGAP patients with its development candidate, CMP-SYNGAP-01.

View all News and Press Releases